BIOLOGICAL TESTING FACILITY - "CONTRACEPTIVE TARGET WEB APPLICATIONS"

生物测试设施 - “避孕目标网络应用程序”

• 批准号: 10361637
• 负责人: Toufan Parman
• 金额: $ 19.98万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-07 至 2023-01-06
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10361637
• 关键词: Area; Bioinformatics; Biological Testing; Clinical; Clinical Trials; Collaborations; Contraceptive Agents; Contraceptive Availability; Contraceptive Devices; Data; Databases; Development; Devices; Drug Formulations; Evaluation; In Vitro; Internet; Investigational New Drug Application; Knowledge; Maintenance; Pharmaceutical Preparations; Phase; Preparation; Process; Research Personnel; Safety; System; Toxicology; Update; Work; contraceptive target; design; drug discovery; drug testing; efficacy evaluation; in vivo; next generation; novel; novel strategies; pre-clinical; reproductive; stability testing; user-friendly; web app; web site

One major obstacle in early phase non-steroidal contraceptive discovery and development is limited by known targets and readily accessibility of this information. It is important to facilitate the discovery, curation and availability of contraceptive targets with the aim of developing new approaches to advance next generation of safe contraceptive drug/device. To alleviate this obstacle, bioinformatics driven approach to identify and curate those targets from the existing databases was established. To further allow easy accessibility and friendly user interface for this database, a web application is needed. The Biological Testing Facility has bioinformatics and web design and application capability to achieve this task, in addition to permit rapid evaluation (in vitro and in vivo) of new compositions of matter to the target, efficacy evaluation, safety/ toxicology assessment, drug formulations, delivery systems, and devices for contraceptives followed by clinical batch preparation/ release and continued stability testing of drugs to be evaluated in clinical trials. The BTF provides overall project management and the capabilities to support all phases of novel target product identification, drug discovery/ optimization, preclinical activities and development of contraceptives and associated tasks leading to the filing of investigational new drug (IND) applications.

早期阶段非甾体避孕药发现和开发的一个主要障碍是 受限于已知的目标和该信息的容易获得性。重要的是， 发现、管理和提供避孕目标， 促进下一代安全避孕药物/装置的方法。缓解这一 障碍，生物信息学驱动的方法，以确定和管理这些目标，从现有的 建立了数据库。为了进一步方便访问和友好的用户界面， 需要一个Web应用程序。生物试验机构具有生物信息学和网络 设计和应用能力，以实现这一任务，除了允许快速评估（在 体外和体内）的新组合物的物质的目标，疗效评价，安全性/ 毒理学评估、药物配方、输送系统和避孕器械 随后进行临床批次制备/放行和药物的持续稳定性测试， 在临床试验中进行评估。BTF提供全面的项目管理和能力， 支持新目标产品鉴定、药物发现/优化、临床前 避孕药具的活动和开发及相关任务， 研究性新药（IND）申请。